paclitaxel has been researched along with Adverse Drug Event in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.00) | 18.2507 |
| 2000's | 18 (18.00) | 29.6817 |
| 2010's | 63 (63.00) | 24.3611 |
| 2020's | 16 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Adams Curry, M; Cebollero, J; LaFollette, JA; Walton, SM | 1 |
| Chen, Y; Gan, P; Lu, R; Wang, Y | 1 |
| Acar, R; Akcan, E; Aykan, MB; Erturk, I; Karadurmus, N; Yildiran, GS | 1 |
| Grant, CV; Jordan, K; Pyter, LM; Seng, MM | 1 |
| Dülgar, Ö; Elleson, KM; Markowitz, J; Saha, A | 1 |
| Eikenberg, JD; Engel, C; Quan, EY; Rush, PS | 1 |
| Brule, SY; Moore, SM; Robinson, J; Tsang, C; Wheatley-Price, PF | 1 |
| Bleilevens, A; Li, X; Maurer, J; Stickeler, E; Strietz, J | 1 |
| Cheng, MH; Chou, PL; Fang, YP; Huang, YP; Rau, KM | 1 |
| Ardizzoni, A; Barbieri, F; Boni, L; Brocchi, S; Cavanna, L; Cinieri, S; Colantonio, I; Dazzi, C; Delmonte, A; Frassoldati, A; Gelsomino, F; Lamberti, G; Longo, L; Riccardi, F; Sperandi, F; Tiseo, M; Tofani, L | 1 |
| Jošt, M; Kopač, P; Koren, A; Korošec, P; Lainščak, M; Mangaroski, D | 1 |
| Arun, BK; Ayoub, JP; Bondarenko, I; Campone, M; Diéras, V; Dudley, M; Friedlander, M; Han, HS; Jakobsen, EH; Jalving, M; Kaufman, B; Khandelwal, N; Kundu, MG; Maag, D; Oprean, C; Palácová, M; Park, YH; Puhalla, SL; Ratajczak, CK; Shparyk, Y; Wildiers, H; Yañez, E | 1 |
| de Wiljes, J; Hartung, N; Huisinga, W; Kloft, C; Maier, C | 1 |
| Francis, KE; Friedlander, M; Gebski, V; Lee, CK; Lord, SJ; Pujade-Lauraine, E | 1 |
| Cruz, RAC; Díaz, SNG; González, RVV; Gutiérrez, OV; Quezada, CEL | 1 |
| Cleenewerk, L; Eijkelkamp, N; Hiensch, AE; May, AM; Vermeer, CJC | 1 |
| Fujita, Y; Harada, T; Ichinose, M; Inoue, A; Kato, T; Maemondo, M; Miyauchi, E; Nakagawa, T; Saito, H; Sugawara, S; Suzuki, T; Usui, K; Watanabe, H | 1 |
| Hayashi, A; Itoga, M; Kumagai, M; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Taima, K; Takanashi, S; Tanaka, H; Tanaka, Y; Tasaka, S; Yasugahira, H | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Ameels, H; Baselga, J; Berghorn, M; Borrego, MR; Bozovic-Spasojevic, I; Bradbury, I; Campbell, C; Chen, DR; de Azambuja, E; Di Cosimo, S; Ewer, M; Fumagalli, D; Harbeck, N; Huober, J; Im, YH; Izquierdo, M; Lambertini, M; Maetens, M; Piccart, M; Ponde, N; Pusztai, L; Rodeheffer, R; Suter, T; Zardavas, D | 1 |
| Abu-Khalaf, M; Brandt, DS; Burrello, T; Chagpar, A; DiGiovanna, MP; Foldi, J; Frederick, C; Hatzis, C; Hofstatter, EW; Horowitz, N; Killelea, B; Lannin, D; Mougalian, S; Pusztai, L; Rispoli, L; Sabbath, K; Sanft, T; Silber, A | 1 |
| Laoitthi, P; Parinyanitikul, N; Poovorawan, N; Rattananupong, T; Sithidetphaiboon, P; Sriuranpong, V; Tanpipattanakul, W; Thanasanvimon, S | 1 |
| Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C | 1 |
| Bandapalli, OR; Campo, C; da Silva Filho, MI; Försti, A; Goldschmidt, H; Hemminki, K; Mahmoudpour, SH; Merz, M | 1 |
| Bae, ON; Bian, Y; Chang, YK; Chung, JH; Kim, K; Lim, KM | 1 |
| Arroyo-Conde, C; Casanova-Martinez, C; González-Costas, S; Piñeiro-Corrales, G; Romero-Ventosa, EY | 1 |
| Anders, CK; Basch, E; Carey, LA; Choi, SK; Deal, AM; Dees, EC; Jolly, TA; Karuturi, MS; Kimmick, GG; Lee, JT; Muss, HB; Nyrop, KA; Reeder-Hayes, KE; Reeve, BB; Reinbolt, RE; Shachar, SS; Speca, JC; Wood, WA | 1 |
| Chen, QY; Guo, L; Guo, SS; Li, XY; Liang, YJ; Lin, C; Lin, HX; Liu, LT; Liu, SL; Mai, HQ; Sun, XS; Tang, LQ; Tang, QN; Wen, YF; Xie, HJ; Yan, JJ; Yang, ZC | 1 |
| Aiba, K; Hayashi, T; Kikkawa, F; Kogawa, T; Matsui, R; Mizuno, M; Saeki, T; Shimokawa, M; Tamura, K | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Celio, L; Festinese, F; Lepori, S; Lorusso, D; Niger, M; Raspagliesi, F; Saibene, G | 1 |
| Mashayekhi-Sardoo, H; Mohammadpour, AH; Nomani, H; Sahebkar, A | 1 |
| Cortot, AB; Delourme, J; Dhalluin, X; Habib, S; Lafitte, JJ; Petyt, G; Scherpereel, A; Tacelli, N | 1 |
| Axelrod, RS; Bradley, JD; Buyyounouski, MK; Komaki, R; Langer, C; Lawrence, YR; Machtay, M; Movsas, B; Paulus, R; Smith, C; Wasserman, T; Werner-Wasik, M | 1 |
| de Bruijn, P; de Graan, AJ; de Raaf, PJ; Elens, L; Engels, FK; Eskens, FA; Friberg, LE; Mathijssen, RH; Sparreboom, A; Sprowl, JA; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Kudlowitz, D; Muggia, F | 1 |
| Kim, JH; Kim, JW; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ; Yim, GW | 1 |
| Agarwal, S; Beckman, J; Cotreau, MM; Dickler, MN; Duarte, A; Mayer, EL; Richly, H; Scheulen, ME; Steelman, L; Strahs, AL; Winer, EP | 1 |
| Apte, TG; Bhattacharyya, GS; Dasare, RR; Joshi, DA; Kasbekar, RB; Lopes, GL; Mengde, SD; Parikh, PM; Patil, PP; Phadke, GK; Ranade, AA | 1 |
| Awada, A; Bakshi, AV; Bondarenko, IN; Bonneterre, J; Ferrero, JM; Nowara, E; Piccart, M; Wilke, C | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Burtness, BA; Forastiere, AA; Ghebremichael, M; Hancock, MR; Lee, J; Pectasides, E; Psyrri, D; Ridge, JA; Rimm, D; Rosen, FR; Spencer, SA; Tolba, KA; Wanebo, HJ | 1 |
| Aliño, SF; Bosó, V; de la Cueva, H; Herrero, MJ; Marqués, MR; Megias, JE; Montalar, J; Palomar, L; Poveda, JL; Rojas, L; Santaballa, A | 1 |
| Bessette, P; Brown, C; Cretin, J; Dell'Anna, T; du Bois, A; Ferrero, A; Gladieff, L; Havsteen, H; Lorusso, D; Mahner, S; Meier, W; Pujade-Lauraine, E; Vasey, P; Vergote, I; Zeimet, AG | 1 |
| Bhatt, K; Bury, MJ; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Goel, R; Jacobs, SA; Johannes, H; Julian, TB; Mamounas, EP; Provencher, L; Rastogi, P; Robidoux, A; Stella, PJ; Swain, SM; Tan, AR; Thirlwell, MP; Wolmark, N | 1 |
| Gardner, PH; Knapp, P; Woolf, E | 1 |
| Masocha, W | 1 |
| Ascierto, PA; Bryce, A; Chmielowski, B; D'Angelo, SP; Grob, JJ; Grossmann, KF; Gutzmer, R; Hassel, JC; Hodi, FS; Hoeller, C; Horak, C; Khushalani, NI; Krackhardt, AM; Lambert, A; Lao, CD; Larkin, J; Linette, GP; Lorigan, P; Maio, M; Miller, WH; Minor, D; Mohr, P; Neyns, B; Svane, IM; Sznol, M; Thomas, L; Weber, JS; Yang, AS | 1 |
| Bonanno, L; Canova, F; Carli, P; Conte, P; Favaretto, A; Pasello, G; Polo, V; Urso, L; Zago, G | 1 |
| Casak, SJ; Chen, H; Dougherty, M; Fashoyin-Aje, I; He, K; Helms, W; Jin, R; Keegan, P; Kennett, S; Khasar, S; Lemery, SJ; Li, H; Novak, R; Pazdur, R; Zhang, H; Zhang, L; Zhao, H; Zhao, L | 1 |
| Atkinson, T; Basch, E; Bennett, A; Kris, MG; Pietanza, MC; Rogak, LJ; Schrag, D; Shaw, M; Shouery, M; Sima, CS; Wood, WA | 1 |
| Gong, J; Jia, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Zhang, X; Zhou, J | 1 |
| Bowman, L; John, W; Liepa, AM; Melemed, A; Peterson, P; Shen, W; Smyth, EN | 1 |
| Bach, BA; Bamias, A; Brize, A; Coleman, RL; DeCensi, A; Fabbro, M; Fujiwara, K; Lhommé, C; Monk, BJ; Oaknin, A; Provencher, D; Raspagliesi, F; Ray-Coquard, I; Vergote, I; Vogl, FD; Zhang, K | 1 |
| Awada, A; Bachelot, T; Badwe, RA; Bondarenko, I; Bose, R; Bryce, R; Carey, LA; Colomer, R; Demetriou, G; Deo, S; Goswami, C; Inoue, K; Kim, SB; Lee, SC; Mehta, AO; Wong, A; Xu, F; Yao, B | 1 |
| Asselain, B; Bachelot, T; Brain, E; Cailliot, C; Campone, M; Chenuc, G; Courtinard, C; Dalenc, F; Debled, M; Delaloge, S; Dieras, V; Ferrero, JM; Goncalves, A; Guesmia, T; Jacot, W; Jouannaud, C; Kerbrat, P; Levy, C; Lorgis, V; Mouret-Reynier, MA; Pérol, D; Petit, T; Robain, M; Uwer, L; Vanlemmens, L; Veyret, C | 1 |
| Behringer, DM; Eberhardt, W; Fischer, JR; Gauler, TC; Henrich, A; Hilger, RA; Jaehde, U; Joerger, M; Kimmich, M; Kloft, C; Ko, YD; Kopp, HG; Kraff, S; Mayer, F; Miller, MC; Moritz, B; Mueller, L; Reck, M; Reinmuth, N; Roessler, M; Salamone, SJ; von Pawel, J | 1 |
| Bertelli, G; Drews, F; Lutchman-Singh, K | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Chen, Q; Flowers, CR; Goldstein, DA; Kohn, CG; Montero, AJ; Zeichner, SB | 1 |
| Castell, C; Jiang, J; Lager, J; Liu, L; Mutch, D; Traynor, AM; Wheler, J | 1 |
| Chu, SC; Kao, RH; Li, CC; Wang, TF; Yao, CY | 1 |
| Bartelheim, K; Christopeit, M; Forstpointner, R; Kühnbach, R; Lenz, G; Naujoks, K; Schalhorn, A | 1 |
| Aogi, K; Kakishita, T; Nishikawa, K; Ohama, Y; Okita, A; Okita, R; Saeki, T; Taira, N; Takashima, S | 1 |
| Carrigan, N; Gardner, PH; Knapp, P; Raynor, DK; Woolf, E | 1 |
| Barry, JJ; Boden, M; Huibregtse, B; Kangas, S; Richard, R; Schwarz, MC | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| DI, W; Feng, QM; Wu, X | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Eren, B; Karaduman, D; Keles, ON | 1 |
| Minami, H; Mukohara, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N | 1 |
| Bao, YJ; Hou, W; Hua, BJ; Xu, WR | 1 |
| Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A | 1 |
| Ran, S; Ray, MA; Toth, LA; Trammell, RA; Verhulst, S | 1 |
| Bennett, CL; Bookstaver, PB; Campbell, W; Garg, V; Norris, LB; Qureshi, ZP; Raisch, DW | 1 |
| Daladimos, T; Kalinoglou, N; Karabelis, A; Kosmas, C; Moschovis, D; Mylonakis, N; Panagiotidi, E; Papachrysanthou, T; Politis, P; Tsakonas, G; Tsavaris, N; Vorgias, G | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Ando, M; Fujiwara, Y; Harano, K; Hashimoto, K; Hirakawa, A; Katsumata, N; Kinoshita, T; Shimizu, C; Tamura, K; Tanabe, Y; Yonemori, K; Yunokawa, M | 1 |
| Li, L; Wang, M; Zhang, L; Zhao, X; Zhong, W | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Brenner, A; Castaigne, JP; Drappatz, J; Eichler, A; Elian, K; Fielding, RM; Groves, MD; Kelsey, S; Lawrence, B; Meyers, CA; Mikkelsen, T; Rosenfeld, S; Sarantopoulos, J; Schiff, D; Shing, M; Wang, X; Wen, PY; Wong, ET | 1 |
| Brassard, M; Budman, DR; Cohen, G; Dhami, M; George, T; Glaspy, J; Hackett, J; Holmes, FA; Jones, SE; Liang, BC; Meza, L; O'Shaughnessy, J; Richards, D; Savin, M; Vukelja, S; Yang, BB | 1 |
| Diepolder, H; Heinemann, V; Kenngotte, S; Stemmler, HJ | 1 |
| Bogliun, G; Cavaletti, G; Colombo, N; Cundari, S; Fei, F; Lissoni, A; Marzorati, L; Parma, G; Piatti, M; Zanna, C; Zincone, A | 1 |
| Jassem, J; Senkus-Konefka, E | 1 |
| Balis, F; Bates, S; Cole, D; Egorin, MJ; Flynn, BM; Fojo, T; Knutsen, T; Langham, G; Rao, VK; Ried, T; Steinberg, SM; Wangsa, D | 1 |
| Argyriou, AA; Assimakopoulos, K; Chroni, E; Gourzis, P; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Fujita, H; Honjo, H; Hosokawa, K; Kato, Y; Kinoshita, Y; Kuroboshi, H; Mori, T; Nakata, Y; Watanabe, A; Yamaguchi, T; Yasuda, J | 1 |
| Barnadas, A; Basterrechea, L; Capdevila, J; Ciria, JP; Farré, N; Gomez-Segura, G; Membrive, I; Pallarés, C; Paredes, A | 1 |
| Avallone, A; Comella, P; Costanzo, R; Frasci, G; Gambardella, A | 1 |
| Boggess, JF; Brady, MF; Burger, RA; Clarke-Pearson, DL; Hanly, M; Lee, RB; Mannel, R; Spriggs, DR; Vaccarello, L | 1 |
| Graziano, SL; Green, MR; Herndon, JE; Socinski, MA; Vokes, E; Wang, X; Watson, D | 1 |
| Behrens, BC; Ding, M; Robinson, JM; Vandré, DD | 1 |
| Abati, A; Carter, C; Chang, YN; Chiang, Y; Chow, C; Cowan, KH; Cusack, G; Dunbar, C; Goldspiel, B; Gottesman, MM; Hines, K; Huang, H; Leitman, SF; McDonagh, K; Moscow, JA; Nienhuis, A; Noone, M; O'Shaughnessy, J; Pastan, I; Read, EJ; Schneider, E; Sorrentino, B; Steinberg, S; Wilson, W; Zujewski, JA | 1 |
6 review(s) available for paclitaxel and Adverse Drug Event
| Article | Year |
|---|---|
Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis.
Topics: Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypersensitivity; Male; Middle Aged; Nanoparticles; Network Meta-Analysis; Paclitaxel | 2020 |
Neuro-immune interactions in paclitaxel-induced peripheral neuropathy.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Neuroimmunomodulation; Paclitaxel; Peripheral Nervous System Diseases | 2021 |
The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperglycemia; Insulin; Neoplasms; Paclitaxel | 2019 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Cohort Studies; Docetaxel; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Paclitaxel; Premedication; Taxoids; United States; United States Food and Drug Administration | 2011 |
43 trial(s) available for paclitaxel and Adverse Drug Event
| Article | Year |
|---|---|
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Prospective Studies; Small Cell Lung Carcinoma | 2020 |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carboplatin; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Treatment Outcome | 2020 |
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Survival Rate | 2021 |
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Male; Paclitaxel; Treatment Outcome | 2017 |
A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel | 2017 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
Topics: Aged; Biomarkers; Breast Neoplasms; Cardiotoxicity; Cardiovascular Abnormalities; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Troponin T | 2018 |
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Taxoids; Trastuzumab | 2018 |
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.
Topics: Adult; Aged; Carboplatin; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Genital Neoplasms, Female; Humans; Italy; Middle Aged; Nausea; Olanzapine; Paclitaxel; Palonosetron; Surveys and Questionnaires; Vomiting | 2019 |
The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2013 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.
Topics: Aged; Carboplatin; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms | 2013 |
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
Topics: Adult; Aged; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Endothelial Cells; Female; Humans; Lipids; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2014 |
Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Carboplatin; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Epithelial Cells; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2014 |
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Recurrence | 2015 |
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Indazoles; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Sulfonamides | 2015 |
Combined verbal and numerical expressions increase perceived risk of medicine side-effects: a randomized controlled trial of EMA recommendations.
Topics: Adolescent; Adult; Aged; Attitude to Health; Communication; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Government Regulation; Humans; Male; Middle Aged; Paclitaxel; Risk Assessment; Young Adult | 2016 |
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CTLA-4 Antigen; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Male; Melanoma; Middle Aged; Neoplasm Staging; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf | 2015 |
FDA Approval Summary: Ramucirumab for Gastric Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2015 |
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2016 |
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2016 |
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Placebo Effect; Quality of Life; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Quinolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2016 |
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2017 |
A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Survival Analysis | 2008 |
Perceived risk of medicine side effects in users of a patient information website: a study of the use of verbal descriptors, percentages and natural frequencies.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Attitude to Health; Culture; Drug Information Services; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ibuprofen; Internet; Male; Medication Adherence; Middle Aged; Paclitaxel; Risk Assessment; Semantics; Young Adult | 2009 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Linear Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Neurotoxicity Syndromes; Paclitaxel | 2010 |
[Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs].
Topics: Acupuncture Points; Acupuncture Therapy; Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases | 2010 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
[Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2012 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
Phase I study of GRN1005 in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Peptides | 2013 |
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Probability; Recombinant Proteins; Reference Values; Taxoids; Treatment Outcome | 2002 |
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Survival Analysis; Taxoids | 2007 |
Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Failure | 2007 |
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 2007 |
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Paclitaxel; Survival Analysis | 2008 |
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Combined Modality Therapy; DNA, Complementary; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Paclitaxel; Pilot Projects; Polymerase Chain Reaction; Retroviridae; T-Lymphocyte Subsets; Transduction, Genetic; Transplantation, Autologous | 1999 |
51 other study(ies) available for paclitaxel and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evaluation of a Pharmacist-Developed, Nurse-Driven Protocol for Management of Parenteral Anticancer Therapy Infusion Reactions in an Ambulatory Infusion Center.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Infusions, Intravenous; Paclitaxel; Pharmacists; Retrospective Studies | 2023 |
Shaoyao Gancao Decoction Ameliorates Paclitaxel-Induced Peripheral Neuropathy via Suppressing TRPV1 and TLR4 Signaling Expression in Rats.
Topics: Animals; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Hyperalgesia; Myeloid Differentiation Factor 88; Paclitaxel; Peripheral Nervous System Diseases; Rats; Toll-Like Receptor 4; TRPV Cation Channels | 2022 |
Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours.
Topics: Adult; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasms, Germ Cell and Embryonal; Observational Studies as Topic; Oxaliplatin; Paclitaxel | 2022 |
Antibiotic treatment inhibits paclitaxel chemotherapy-induced activity deficits in female mice.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Cognitive Dysfunction; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Mice; Paclitaxel | 2023 |
Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ipilimumab; Melanoma; Nivolumab; Paclitaxel; Skin Neoplasms; Syndrome | 2023 |
Paclitaxel-induced dorsal hand-foot syndrome.
Topics: Aged; Drug-Related Side Effects and Adverse Reactions; Foot; Hand-Foot Syndrome; Humans; Male; Paclitaxel; Quality of Life | 2023 |
The utility of H2 receptor antagonists in preventing infusion-related reactions to paclitaxel chemotherapy.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Paclitaxel; Premedication; Retrospective Studies | 2023 |
Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Paclitaxel; Primary Cell Culture; Survival Analysis; Triple Negative Breast Neoplasms | 2020 |
Unsuccessful Desensitization to Paclitaxel in a Patient With High Basophil Sensitivity.
Topics: Antineoplastic Agents; Basophil Degranulation Test; Basophils; Breast Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Paclitaxel; Treatment Failure | 2021 |
Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bayes Theorem; Biomarkers, Pharmacological; Clinical Decision Rules; Computer Simulation; Drug Development; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Learning; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neutropenia; Paclitaxel; Patient Reported Outcome Measures; Quality Improvement; Reinforcement, Psychology; Safety; Treatment Outcome; Uncertainty | 2021 |
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization.
Topics: Adult; Breast Neoplasms; Desensitization, Immunologic; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypersensitivity, Immediate; Male; Paclitaxel; Retrospective Studies | 2022 |
Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Bridged-Ring Compounds; Cohort Studies; Dexamethasone; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Middle Aged; Paclitaxel; Premedication; Retrospective Studies; Taxoids | 2018 |
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2018 |
Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Topics: Aged; Bortezomib; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Risk Factors; Taxoids; Vincristine | 2018 |
Pro-Coagulant and Pro-Thrombotic Effects of Paclitaxel Mediated by Red Blood Cells.
Topics: Adolescent; Animals; Antineoplastic Agents; Cell-Derived Microparticles; Drug-Related Side Effects and Adverse Reactions; Erythrocytes; Human Umbilical Vein Endothelial Cells; Humans; Male; Neoplasms; Paclitaxel; Phosphatidylserines; Phospholipid Transfer Proteins; Rats; Rats, Sprague-Dawley; Thrombin; Thrombosis; Young Adult | 2018 |
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2019 |
Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Herpesvirus 4, Human; Humans; Liposomes; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids | 2018 |
Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.
Topics: Aged; Antiemetics; Carboplatin; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Genital Neoplasms, Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nausea; Paclitaxel; Prospective Studies; Vomiting | 2019 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies | 2013 |
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Polymorphism, Single Nucleotide; Sex Characteristics | 2013 |
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Treatment Outcome | 2013 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
SNPs and taxane toxicity in breast cancer patients.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Cytochrome P-450 CYP3A; DNA-Binding Proteins; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Mucositis; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids | 2014 |
Comprehensive analysis of the GABAergic system gene expression profile in the anterior cingulate cortex of mice with Paclitaxel-induced neuropathic pain.
Topics: Animals; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Mice; Neuralgia; Paclitaxel; Receptors, GABA-A; RNA, Messenger; Transcriptome | 2015 |
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Small Cell Lung Carcinoma | 2015 |
Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Information Dissemination; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Reported Outcome Measures; Pemetrexed; Research Personnel; Self Report | 2016 |
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2016 |
Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in 'Real-world' Patients.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Carboplatin; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2016 |
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Health Care Costs; Humans; Ipilimumab; Markov Chains; Melanoma; Models, Economic; Nivolumab; Paclitaxel; Proto-Oncogene Proteins B-raf; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Capsules; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Liposomes; Male; Paclitaxel; Time Factors | 2008 |
Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Tissue Distribution; Toremifene; Treatment Outcome | 2009 |
In vitro and in vivo evaluation of the safety and stability of the TAXUS Paclitaxel-Eluting Coronary Stent.
Topics: Animals; Blood Vessel Prosthesis; Coronary Restenosis; Coronary Vessels; Drug Stability; Drug-Eluting Stents; Drug-Related Side Effects and Adverse Reactions; Equipment Design; Equipment Failure Analysis; Equipment Safety; Iliac Artery; Male; Paclitaxel; Rabbits; Treatment Outcome | 2009 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[Immune reconstitution in advanced ovarian cancer patients undergoing first line chemotherapy].
Topics: Animals; Carboplatin; CD24 Antigen; CD47 Antigen; Cell Count; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunotherapy; Lymphocyte Subsets; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; T-Lymphocytes, Regulatory; Time Factors | 2009 |
The protective effect of beta-1,3-D-glucan on taxol-induced hepatotoxicity: a histopathological and stereological study.
Topics: Animals; Antioxidants; beta-Glucans; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Free Radical Scavengers; Gastrointestinal Diseases; Glucans; Liver; Liver Diseases; Mice; Necrosis; Oxidative Stress; Paclitaxel; Proteoglycans; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2010 |
Development of a mouse model for assessing fatigue during chemotherapy.
Topics: Animals; Circadian Rhythm; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Nanoparticles; Neoplasms; Neurologic Examination; Paclitaxel; Sleep | 2011 |
Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.
Topics: Adnexal Diseases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Mixed Tumor, Malignant; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2011 |
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Young Adult | 2013 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Gastrointestinal toxicity associated with weekly docetaxel treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Digestive System; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enterocolitis; Fatal Outcome; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Organ Failure; Neoplasm Staging; Paclitaxel; Risk Assessment; Taxoids | 2002 |
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ifosfamide; Neurologic Examination; Paclitaxel; Peripheral Nervous System Diseases; Severity of Illness Index; Taxoids; Uterine Cervical Neoplasms | 2003 |
Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Biotransformation; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gene Expression Profiling; Genes, p53; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Paclitaxel; Pharmacogenetics; Tamoxifen; Trastuzumab | 2004 |
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Topics: Animals; Area Under Curve; Azure Stains; Bone Marrow Cells; Chromosome Aberrations; Chromosome Painting; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Infusions, Intravenous; Macaca mulatta; Neutropenia; Paclitaxel; Thiotepa | 2005 |
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Female; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies | 2006 |
The microtubule cytoskeleton in human phagocytic leukocytes is a highly dynamic structure.
Topics: Drug-Related Side Effects and Adverse Reactions; Eosinophils; Female; Fluorescent Antibody Technique; Humans; Leukocytes; Microtubules; Monocytes; Neutrophils; Nocodazole; Ovarian Neoplasms; Paclitaxel; Phagocytes; Tubulin | 1995 |
New approach reduces side effects of high-dose chemotherapy for breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Paclitaxel; Prognosis | 1999 |